Loxiglumide protects against experimental pancreatitis.
Loxiglumide (D,L-4-(3,4-dichloro-benzoylamino)- 5-(N-3-methoxypropyl-pentylamino)-5-oxo-pentanoic acid, CR 1505) is a derivative of pentanoic acid and belongs to a newly discovered class of agents with cholecystokinin antagonistic activities. Loxiglumide has preventive effects on different types of experimental pancreatitis, induced e.g. by ceruletide (i.p. ED50 ca. 9 mumol/kg), by intrapancreatic taurocholate (i.p. ED50 ca. 80 mumol/kg) or by choline-deficient ethionine-supplemented diet (i.p. ED50 ca. 45 mumol/kg). Loxiglumide has a simple, non-polypeptidic chemical structure and may be a candidate for clinical investigations in man, e.g. for pancreatitis.
Setnikar
I
I
Rotta Research Laboratorium, Monza, Italy.
Bani
M
M
Cereda
R
R
Chisté
R
R
Makovec
F
F
Pacini
M A
MA
Revel
L
L
D000818:Animals; D002108:Ceruletide; D004032:Diet; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives*; D008297:Male; D051379:Mice; D010195:Pancreatitis / Q000139:chemically induced / Q000517:prevention & control*; D011377:Proglumide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D013656:Taurocholic Acid
D005973:Glutamine; D013656:Taurocholic Acid; C053737:loxiglumide; D002108:Ceruletide; D011377:Proglumide